Ohana Biosciences Completes Enrollment in the SPRING Clinical Trial for Spertility, a Novel Sperm Cell Treatment to Improve Outcomes in Assisted Reproductive Technology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ohana Biosciences, a pioneering reproductive health company that created the world’s first sperm biology platform for sperm-based products, today announced it has completed patient enrollment in its SPRING study (SPeRtility, IVF Next Generation) of Spertility™. Spertility is a sperm cell treatment designed to improve outcomes for people using Assisted Reproductive Technology (ART), such as In-Vitro Fertilization (IVF). “Completing enrollment in our initial cli ...
